CD Bioparticles offers aptamer screening services to provide rapid and accurate screening for aptamers with high affinity and specificity, resulting in cost savings for our customers' experimental projects. We provide an one-stop in vitro aptamer screening service that flexibly exploits the natural evolution of ligand systems through our exponential enrichment (SELEX) approach. Choose to work with us and you will get the ideal results.
Nucleic acid aptamers have an affinity for target molecules similar to the way antibodies work and show great potential to replace antibodies in biosensors, immediate diagnostics, therapeutics, and all areas currently dominated by antibodies. Once aptamers are identified, they can be produced at less than 10% of the cost of antibody production.
Aptamers are highly structured small molecules of DNA or RNA, and their screening is typically done using the SELEX method. The basic process of SELEX consists of the following.
Fig.1 Schematic illustration of the aptamer generation by conventional SELEX process. (Xu Y, et al., 2021)
CD Bioparticles offers a wide range of unique aptamer screening services for custom aptamer development assays, our services include but are not limited to the following
Applicable targets for SELEX aptamer screening service: proteins, small molecules, cells, bacteria, etc.
Protein delivery requirements: provide protein size, volume, concentration, protein buffer formulation, protein gel map, whether the protein contains a label and the corresponding label information.
Small molecule delivery requirements: provide information on sample gram, concentration, volume, storage environment.
Cellular and bacterial target related: send the specific delivery requirements and sample volume after consultation.
NGS sequencing results, complete experimental report (experimental steps, enrichment rate data during screening and relevant photos, etc.)
CD Bioparticles has rich experience in nucleic acid aptamer screening, and can provide screening and synthesis services for different target-based nucleic acid aptamers, and finally deliver at least 1 nucleic acid aptamer sequence with KD<300 nM. If you are interested in our services, please do not hesitate to contact us for more detailed information.
Quotations and Ordering